Sinopharm’s Beijing and Wuhan subsidiaries have both produced vaccines. Photo: Reuters Sinopharm’s Beijing and Wuhan subsidiaries have both produced vaccines. Photo: Reuters
Sinopharm’s Beijing and Wuhan subsidiaries have both produced vaccines. Photo: Reuters

Chinese drug firm Sinopharm finally publishes Covid-19 vaccine trial data

  • Interim phase 3 results suggest two products have efficacy above 70 per cent for symptomatic cases but there is little data on elderly and vulnerable groups
  • More than 200 million doses have already been administered worldwide and a vaccine made by the firm’s Beijing subsidiary has been approved by the WHO

Topic |   Coronavirus pandemic
Sinopharm’s Beijing and Wuhan subsidiaries have both produced vaccines. Photo: Reuters Sinopharm’s Beijing and Wuhan subsidiaries have both produced vaccines. Photo: Reuters
Sinopharm’s Beijing and Wuhan subsidiaries have both produced vaccines. Photo: Reuters
READ FULL ARTICLE